Rocuronium bromide is a muscle relaxant used during surgery and anesthesia to paralyze muscles so doctors can perform procedures more easily and safely.[1] Esmeron is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
Esmeron is one of 67 small molecule programs targeting Bladder Tumor. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
49 competitors in Morbid Obesity
Lovenox
Ozempic
Mounjaro
Precedex
Prilosec
Xylocaine
Arixtra
Imcivree
Bridion
Ultiva
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details